Other Vaccines - Saudi Arabia

Saudi Arabia

Highlights

The Other Vaccines market in Saudi Arabia is expected to witness a significant revenue growth, with projections indicating a reach of US$258.60m in 2024.
Furthermore, it is anticipated that the market will exhibit a compound annual growth rate (CAGR 2024-2029) of 9.96%, ultimately leading to a market volume of US$415.80m by 2029.
When comparing globally, United States is poised to generate the highest revenue, amounting to US$24.73bn in 2024.
Saudi Arabia has seen a surge in demand for other vaccines due to increasing awareness and proactive measures taken by the government to ensure public health.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Saudi Arabia has seen significant growth in recent years.

Customer preferences: The Saudi Arabian population has become more aware of the importance of preventative healthcare measures, including vaccination. This has led to an increase in demand for Other Vaccines, which protect against diseases such as meningitis and pneumonia.

Trends in the market: One of the key trends in the Other Vaccines market in Saudi Arabia is the increasing use of combination vaccines. These vaccines offer protection against multiple diseases in a single shot, which is particularly appealing to parents of young children. Additionally, there has been a growing trend towards personalized vaccination schedules, with some individuals opting for additional booster shots to ensure maximum protection against specific diseases.

Local special circumstances: Saudi Arabia has a large expatriate population, which has contributed to the growth of the Other Vaccines market. Many expats come from countries with different vaccination schedules and requirements, leading to increased demand for certain types of vaccines. Additionally, the Saudi Arabian government has implemented a number of vaccination campaigns in recent years, which has helped to raise awareness of the importance of vaccination among the general population.

Underlying macroeconomic factors: Saudi Arabia has a high per capita income and a well-developed healthcare system, which has contributed to the growth of the Other Vaccines market. Additionally, the country has a young population, with a large proportion of children under the age of 18. This demographic trend has led to increased demand for pediatric vaccines, including Other Vaccines. Finally, the Saudi Arabian government has made significant investments in the healthcare sector in recent years, including the construction of new hospitals and healthcare facilities. This has helped to drive demand for a wide range of healthcare products and services, including vaccines.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.